Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow® Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children
Key Highlights
- ➤Nuwellis secures exclusive U.S. distribution rights for Zorro-Flow pediatric urine collection system
- ➤Full U.S. commercialization begins in the first quarter of 2027
- ➤Zorro-Flow supports non-invasive urine collection and early kidney dysfunction recognition
- ➤Zorro-Flow infant male products expected in the second quarter of 2027
- ➤Nuwellis’ Aquadex platform adopted by 47 top U.S. children’s hospitals
Expert Statements
Mike McCormick, President and Chief Executive Officer of Nuwellis
“Accurately understanding urine output in our most vulnerable pediatric patients can provide clinicians with critical information about kidney function; yet, the tools traditionally available to collect and measure urine have significant limitations.”
Mike McCormick, President and Chief Executive Officer of Nuwellis
“Zorro-Flow addresses an important unmet need with a non-invasive solution designed specifically for neonates and small children. With Nuwellis already deeply engaged with pediatric care teams across the country, we are well positioned to bring this technology to hospitals to ensure that babies and small children have the products they need.”
David Askenazi, Professor of Pediatrics and Founder and Chief Scientific Officer at Zorro-Flow Inc.
“Multiple observational studies show that a decrease in urine output is common and associated with mortality, so quantifying urine output in critically ill babies is essential. I have seen firsthand how challenging it is to collect urine in small baby girls whose urethra can be as small as a human hair.”
David Askenazi, Professor of Pediatrics and Founder and Chief Scientific Officer at Zorro-Flow Inc.
“I started Zorro-Flow because babies and small children deserve safe and effective devices designed specifically for them. Partnering with Nuwellis allows us to bring this technology to babies and small children because Nuwellis has strong relationships with pediatric critical care teams across the country.”
Mike McCormick, President and Chief Executive Officer of Nuwellis
“Pediatrics has become an increasingly important part of Nuwellis’ business and long-term strategy.”
Mike McCormick, President and Chief Executive Officer of Nuwellis
“Adding Zorro-Flow to our portfolio allows us to address another critical point in the care pathway by providing clinicians with a better way to assess urine output, adding to the technologies we offer to help manage complex fluid and cardiorenal conditions. Along with Aquadex and Atrility, Zorro-Flow further strengthens our ability to serve pediatric care teams with a broader portfolio of purpose-built technologies.”
MINNEAPOLIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has secured exclusive U.S. distribution rights for the pediatric Zorro-Flow(®) urine collection system. Under the agreement, Nuwellis will serve as the commercial arm for the product in the U.S., further expanding its presence across neonatal and pediatric critical care.
Zorro-Flow is a non-invasive urine collection system designed for neonates and small children, offering clinicians an easy-to-use, safe, effective non-invasive alternative to traditional methods that do not work well.
Get started
Create a free account to read the full story.